title: [COMVp regimen in the treatment of small cell lung cancer--report of 106 patients].
abstract: One hundred and six consecutive small cell lung cancer patients were treated by a combination regimen COMVp (CTX 1,000-1,400 mg IV D 1,8; VCR 1-2 mg IV D 1,8; MTX 20-40 mg IV or IM D 3,5,10,12; VP-16 100 mg IV drip D 3-7; three weeks as a cycle and 2-3 cycles as a course) in our hospital during 1983 to 1984. Among the 95 patients who were evaluated, 10 (10.5%) gave CR, 57 (60%) PR, 19 (20%) no change and 9 (9.5%) progression. The overall response rate was 70.5%. In this paper, factors influencing the response and side effects are also analysed. The data show that COMVp regimen is one of the good front line combination chemotherapy regimens currently available in the management of small cell lung cancer.
authors.affiliation: Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: W B
authors.initials: WB
authors.lastname: Yin
authors.forename: F Y
authors.initials: FY
authors.lastname: Feng
authors.forename: J W
authors.initials: JW
authors.lastname: Wang
authors.forename: Q
authors.initials: Q
authors.lastname: Qiu
authors.forename: Q L
authors.initials: QL
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Bai
authors.forename: J C
authors.initials: JC
authors.lastname: Zhou
authors.forename: S Z
authors.initials: SZ
authors.lastname: Song
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate